Benzoxazole is an aromatic organic compound with a molecular formula of C7H5NO, a benzoxazole ring structure, and an odor similar to pyridine. Although benzoxazole itself has little practical value, many benzoxazole derivatives are commercially important. As heterocyclic compounds, benzoxazoles are used in research as starting materials for the synthesis of larger, often biologically active structures. Its aromaticity makes it relatively stable, although as a heterocycle it has an active site that enables it to be functionalized.
May 28 2024, Insmed announced positive topline results from landmark ASPEN study of Brensocatib in patients with bronchiectasis.
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed for the treatment of patients with bronchiectasis, CRSsNP, and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.
Search 
+86 21 5895 0110 
